Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | CD-1530 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | ATRA | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.7 |
mRNA | BRD-K71781559 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |